Glaxo reports dramatic success with AIDS drug

GlaxoSmithKline's experimental AIDS drug produced dramatic results in a small human study. Researchers say that S/GSK1349572 reduced the virus level 500-fold, according to Bloomberg, and none of the 35 patients involved demonstrated any resistance to the drug.

Virus levels were reduced to undetectable levels in 70 percent of patients and none exhibited the genetic mutations linked with standard therapies now in use.

Michael Saag, director of the Center for AIDS Research at the University of Alabama in Birmingham, described the data as "spectacular." Saag was not involved with the study. "In 10 days to go to undetectable is pretty strong. This thing's working."

- read the story from Bloomberg

Related Articles:
Glaxo promises $97M for new AIDS R&D initiative
Glaxo, Pfizer partner AIDS drugs in new company
Researchers explore new avenue to AIDS vaccine
Nobel winners frustrated, hopeful about AIDS vax
Fauci says HIV vaccine requires a new approach